Biogen has experienced significant business activities that may influence its stock price. The company's investigational
Tau-Targeting Therapy BIIB080 received
FDA Fast Track designation for the treatment of Alzheimer's Disease, which could significantly improve the company's standing. Biogen shares have also reported increases and purchases by companies such as Invesco Ltd, APG Asset Management US Inc, and other institutional players. However, there have also been instances of stock positions being decreased by companies like Russell Investments Group Ltd. Other industry analysts have rated Biogen as one of the
most undervalued biotech stocks to invest in, indicating potential for future value growth. On the other hand, there were reports of Biogen's shares trending downwards for the past five years, and stock downgrades by Argus Research. Despite facing a legal challenge, the company has reported
positive topline results from its study of higher doses of Nusinersen, showing significant benefit in the treatment of SMA, and has made a bid to acquire the remaining stake in Sage Therapeutics.
Biogen BIIB News Analytics from Thu, 01 Aug 2024 07:00:00 GMT to Sat, 12 Apr 2025 11:32:12 GMT -
Rating 2
- Innovation -2
- Information 2
- Rumor -5
